An interventional study of FlorenceM (US) and FlorenceX (UK) and Insulin pump therapy in Diabetes Mellitus, Diabetes Mellitus, Type 1 and Glucose Metabolism Disorders, sponsored by Jaeb Center for Health Research. Completed at 11 sites in 2 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Jaeb Center for Health Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.
Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is the 11th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 with no phase, and was the 27th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 7 · Phase 4 5
First in 2002; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 29 interventional studies, 77 across the 7 observational. Of the 34 that completed or were terminated, 20 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
1 of the studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06959316Jaeb Center for Health ResearchT1D Pregnancy & Me | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with low glucose feature will improve glucose control as measured by HbA1c.
This is an open-label, multi-centre, multi-national, single-period, randomised, parallel group design study, involving a 6 month period of home study during which day and night glucose levels will be controlled either by a closed-loop system combined with low glucose feature (intervention group) or by insulin pump therapy alone (control group).
It is expected that a total of up to 150 subjects (aiming for 130 randomised subjects) with type 1 diabetes will be recruited through paediatric outpatient diabetes clinics of the investigation centres. Participants will all be on subcutaneous insulin pump therapy.
Subjects in the intervention group will have proven competencies both in the use of the study insulin pump and the study continuous glucose monitoring (CGM) device, and will receive appropriate training in the safe use of closed-loop insulin delivery system and low glucose feature. All subjects will have regular contact with the study team during the home study phase including 24/7 telephone support. The primary outcome is between group differences in HbA1c levels at 6 months post study arm initiation. Secondary outcomes are the time spent in the glucose target (3.9 to 10.0mmol/l; 70 to 180mg/dl), time spent with glucose levels above and below target, as recorded by CGM, and other CGM-based metrics. Safety evaluation comprises assessment of the frequency of severe hypoglycaemic episodes and diabetic ketoacidosis (DKA).
Study Objectives:
Surveys investigating participants' quality of life, psychosocial and cognitive functioning, and response to their current treatment will be distributed.
Participants will be fitted with a blinded continuous glucose monitoring (CGM) device to assess baseline glycaemic control. Instructions on how to safely use, remove and send back the device will be provided.
A blood sample will be taken for the measurement of HbA1c and a urine pregnancy test in females of child-bearing potential. A blood sample for centralised analysis of HbA1c will be taken if screening and randomisation are >28 days apart.
Automated day and night closed-loop insulin delivery (intervention arm) combined with low glucose feature (interventional arm) - Participants in the closed-loop group will receive additional training sessions following randomisation covering the use of the study insulin pump and real-time CGM, prior to starting closed-loop insulin delivery.
Once confident with the use of the study pump and CGM system, participants will receive training required for safe and effective use of the closed-loop system approximately 2-4 weeks after randomisation. During this 2-4 hour session participants will operate the system under the supervision of the clinical team. Competency on the use of closed-loop system will be evaluated.
Thereafter, participants are expected to use closed-loop for 6 months without direct real-time remote monitoring.
Subjects will continue using their own insulin pump for 6 months.
3-month and 6 month assessments:
6 months only: Subjects/guardians will be invited to join follow-up focus groups to gather feedback and reactions to their current treatment (closed-loop or insulin pump), the clinical trial, and quality of life changes.
In case of any technical device or problems related to diabetes management such as hypo- or hyperglycaemia, subjects will be able to contact a 24-hour telephone helpline to the local research team at any time. The local research team will have access to central 24 hour advice on technical issues.
--Procedures for safety monitoring during trial: Standard operating procedures for monitoring and reporting of all adverse events will be in place, including serious adverse events (SAE), serious adverse device effects (SADE) and specific adverse events (AE) such as severe hypoglycaemia.
Subjects will be asked to test and record blood ketones if their finger prick glucose is > 16.7mmol/l (300mg/dl) upon awakening, >300 for more than 1 hour, or >22.2mmo/l (400mg/dL) at any time as part of the safety assessment for DKA.
A data safety and monitoring board (DSMB) will be informed of all serious adverse events and any unanticipated serious adverse device effects that occur during the study and will review compiled adverse event data at periodic intervals.
--Criteria for withdrawal of patients on safety grounds: A subject, parent, or guardian may terminate participation in the study at any time without necessarily giving a reason and without any personal disadvantage. An investigator can stop the closed-loop intervention after consideration of the benefit/risk ratio. Possible reasons are:
Efforts will be made to retain subjects in follow up for the final primary outcome assessment even if the intervention is discontinued, unless the investigator believes that it will be harmful for the subject to continue in the trial.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 133 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
Device: FlorenceM (US) and FlorenceX (UK)
Half of the Subjects will continue using their own insulin pump for 6 months.
Device: Insulin pump therapy
The automated closed loop system (FlorenceM in US) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature. The automated closed loop system (FlorenceX in UK) will consist of: The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
Subjects will continue using their own insulin pump for 6 months.
Glycated Hemoglobin (HbA1c) at 6 Months.
The objective is to assess efficacy of day and night automated closed-loop glucose control combined with low glucose feature in improving HbA1c, as compared with insulin pump therapy alone.
Time frame: HbA1c at 6 months
Time Spent in the Target Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl)
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Time Spent Below Target Glucose (3.9mmol/l)(70mg/dl)
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Time Spent Above Target Glucose (10.0 mmol/l) (180 mg/dl)
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Mean and Standard Deviation Sensor Glucose
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Time With Glucose Levels < 3.5 mmol/l (63 mg/dl)
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Time With Glucose Levels <3.0 mmol/l (54 mg/dl)
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Time With Glucose Levels in Significant Hyperglycaemia (Glucose Levels > 16.7 mmol/l) (300mg/dl)
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
Time frame: 6 months
Total Daily Insulin
Units/kg per day
Time frame: 6 months
HbA1c <53 mmol/Mol (<7.0%)
Participants with HbA1c \<53 mmol/mol (\<7.5%) at 6 months
Time frame: 6 months
HbA1c <58 mmol/Mol (<7.5%)
Participants with HbA1c \<58 mmol/mol (\<7.5%) at 6 months
Time frame: 6 months
Relative Reduction ≥10%
Relative reduction in HbA1c ≥10% at 6 months
Time frame: 6 months
HbA1c Absolute Reduction ≥0.5%
HbA1c absolute reduction ≥0.5% from baseline to 6 months
Time frame: 6 months
HbA1c Absolute Reduction ≥1%
HbA1c absolute reduction ≥1% from baseline to 6 months
Time frame: 6 months
HbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%)
Time frame: 6 months
Safety Evaluation
Frequency of severe hypoglycemic episodes as defined by American Diabetes Association (adolescents), and International Society for Pediatric and Adolescent Diabetes (children)
Time frame: 6 months
| Milestone | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Started | 65 | 68 |
| Completed | 59 | 64 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Device issues | 2 | 2 |
The objective is to assess efficacy of day and night automated closed-loop glucose control combined with low glucose feature in improving HbA1c, as compared with insulin pump therapy alone.
| mmol/mol | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Glycated Hemoglobin (HbA1c) at 6 Months. | 60 ± 12 | 64 ± 8 |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| percent of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Time Spent in the Target Glucose Range (3.9 to 10mmol/l) (70 to 180mg/dl) | 54 ± 17 | 47 ± 12 |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| percent of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Time Spent Below Target Glucose (3.9mmol/l)(70mg/dl) | 6.1 (3.0 to 12.1) | 5.4 (2.0 to 12.0) |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| percent of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Time Spent Above Target Glucose (10.0 mmol/l) (180 mg/dl) | 38 ± 20 | 46 ± 15 |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| mmol/L | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Mean and Standard Deviation Sensor Glucose | 9.7 ± 2.9 | 10.1 ± 1.8 |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| percent of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Time With Glucose Levels < 3.5 mmol/l (63 mg/dl) | 7.4 (4.1 to 12.4) | 3.6 (1.0 to 11.6) |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| percent of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Time With Glucose Levels <3.0 mmol/l (54 mg/dl) | 2.9 (1.6 to 6.1) | 1.4 (1.0 to 2.3) |
Secondary endpoints regarding glucose levels will be based on sensor glucose data.
| percent of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Time With Glucose Levels in Significant Hyperglycaemia (Glucose Levels > 16.7 mmol/l) (300mg/dl) | 2.8 (1.8 to 5.4) | 5.7 (3.1 to 11.3) |
Units/kg per day
| units per kg of 24 hour period | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Total Daily Insulin | 1.09 ± 0.27 | 1.03 ± 0.57 |
Participants with HbA1c \<53 mmol/mol (\<7.5%) at 6 months
| participants | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| HbA1c <53 mmol/Mol (<7.0%) | 19 | 4 |
Participants with HbA1c \<58 mmol/mol (\<7.5%) at 6 months
| participants | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| HbA1c <58 mmol/Mol (<7.5%) | 32 | 16 |
Relative reduction in HbA1c ≥10% at 6 months
| participants | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Relative Reduction ≥10% | 22 | 8 |
HbA1c absolute reduction ≥0.5% from baseline to 6 months
| participants | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| HbA1c Absolute Reduction ≥0.5% | 33 | 27 |
HbA1c absolute reduction ≥1% from baseline to 6 months
| participants | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| HbA1c Absolute Reduction ≥1% | 16 | 6 |
| participants | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| HbA1c Absolute Reduction ≥1% or HbA1c <53 mmol/Mol (<7.0%) | 23 | 9 |
Frequency of severe hypoglycemic episodes as defined by American Diabetes Association (adolescents), and International Society for Pediatric and Adolescent Diabetes (children)
| number of severe hypoglycemic events | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Safety Evaluation | 4 | 3 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 24/7 Closed Loop Insulin Delivery | 0/65 (0%) | 4/65 (6.2%) | 0/65 (0%) |
| Insulin Pump Therapy | 0/68 (0%) | 3/68 (4.4%) | 0/68 (0%) |
| Event | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy |
|---|---|---|
| Severe hypoglycemiaEndocrine disorders | 4/65 | 3/68 |
| Age, Continuous(years) | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy | Total |
|---|---|---|---|
| Mean | 131 ± 2.6 | 12.8 ± 2.9 | 13.0 ± 2.8 |
| Sex: Female, Male(Participants) | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy | Total |
|---|---|---|---|
| Female | 37 | 39 | 76 |
| Male | 28 | 29 | 57 |
| Ethnicity (NIH/OMB)(Participants) | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 4 |
| Not Hispanic or Latino | 65 | 64 | 129 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 3 | 3 |
| White | 60 | 53 | 113 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 1 | 4 | 5 |
| Glycated hemoglobin at screening(mmol/mol) | 24/7 Closed Loop Insulin Delivery | Insulin Pump Therapy | Total |
|---|---|---|---|
| Mean | 66 ± 8 | 67 ± 8 | 66 ± 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Aug 2020, 39 months.
Results were first posted in Oct 2026, 6 years 1 month after primary completion.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 39 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research →